Agents that target the epidermal growth factor receptor (EGFR) have demonstrated clinical activity in patients with nonsmall cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer (CRC), and are in clinical development for a range of other solid tumors [1–4]. The gene discussed is EGFR; the disease is pancreatic neoplasm.